Ultralife Q2 margin surge and backlog growth strengthen recovery thesis

What happened

Ultralife's Q2 2026 revenue was essentially flat YoY at $47.9M, but gross margin jumped to 28.9% (26.6% ex‑IEEPA refund) from 23.9% a year ago, driving a tripling of GAAP EPS to $0.15. Operating income included $0.9M in one‑time costs yet still rose to $3.4M from $2.3M, and adjusted EBITDA expanded to $6.1M. The sequential backlog grew to $117.5M, providing visibility and supporting the narrative that demand in the battery franchise remains robust. While the IEEPA refund flatters the headline margin, the underlying 26.6% gross margin and operating improvement suggest the integration and quality issues flagged in prior reports are beginning to abate. However, the Communications Systems segment was not broken out, and the company still faces elevated leverage and interest coverage headwinds.

Implication

The quarter demonstrates that management’s cost and integration efforts are yielding tangible margin gains even with flat sales, and backlog growth offers revenue visibility. This supports an upgrade from POTENTIAL BUY to BUY if subsequent quarters confirm sustained margin expansion and FCF generation, though the balance sheet needs monitoring and Communications Systems weakness is still a risk.

Thesis delta

The sharp margin improvement and backlog build strengthen the bull case that Ultralife’s operational issues are transitory. The thesis shifts from 'wait for execution' to 'execution is commencing,' though a full upgrade requires another quarter of consistent profitability and FCF to address leverage concerns.